Thursday, December 5, 2013
"Last month, the Colorado Office of Economic Development and International Trade announced more than $3 million in grants aimed at helping academic researchers and bioscience companies take research from labs like those at Skaggs to market...
...At CID4, which stands for Colorado Institute for Drug, Device and Diagnostic Development, the grant totaled more than $1.3 million. The agency helps early stage bioscience companies get their companies off the ground and, according to OEDIT, the money will “support operations and the development and management of life-science discoveries.”
Kevin Smith, CID4’s executive director, said the grant shows that the organization, which now has eight companies in its portfolio, is having success...
...April Giles, president and CEO of the Colorado BioScience Association, said that from the industry’s perspective, the grants are hugely important because they can bridge that gap between the research lab and the market place."
Link to the Aurora Sentinel
Tuesday, November 19, 2013
CBSA Commends the State of Colorado For Granting $3.135 Million To Advance Bioscience Research from Bench to Marketplace
Commercial Infrastructure grantees announced by the OEDIT include:
* The Colorado Institute for Drug, Device and Diagnostic Development (CID4): $1,350,000
CID4 is managing life science discoveries from Colorado research institutions and Colorado start-ups and early-stage businesses with the goal of creating bioscience jobs in Colorado. Grant funds support operations and the development and management of life-science discoveries. The CID4 has seven early-stage companies under its guidance supporting their operational development and attracting additional investment to meet their needs. Visit: http://cid4.com
* Colorado Center for Drug Discovery (C2D2): $750,000
Based at Colorado State University, C2D2 is a resource to faculty at Colorado research universities, bringing biology and chemistry faculty together to use chemical libraries, computational resources, bioinformatics, cheminformatics, database support, virtual high throughput screening, and Computer Aided Drug Design to pharmacologically validate drug candidates with patent-protected chemical matter and innovative therapeutics for unmet medical needs. C2D2 supports several inter-institutional projects with funding and resources. Further, C2D2 offers compounds to investigators through its screening library and medicinal chemistry services that are critical in the drug discovery process. Visit: http://c2d2.org
* The Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado: $410,248
The University of Colorado Skagg's School of Pharmacy at Anschutz developed an HTS/HCS (high throughput/content screening) Core Facility for drug discovery. This resource has been utilized by more than 100 researchers and companies advancing the science and helping to secure intellectual property. http://www.ucdenver.edu/academics/colleges/pharmacy/Pages/SchoolofPharmacy.aspx
* The BioFrontiers Institute at the University of Colorado: $624,752
The BioFrontiers Institute is a state-of-the art research and education facility that links the basic sciences, engineering, clinical practice, and industry at the University of Colorado's Boulder campus to support breakthrough developments in areas such as engineering human tissues, RNA enzyme and aptamer-based pharmaceutical, biorefining, and genetics. Grant funds support equipment, resources and personnel costs to develop the core facilities of the institute. With grant support, the institute has developed one of the largest repositories of shRNAs in the world at the Functional Genomics Facility. Colorado companies partner with the institute to improve their products. Ventria, a Fort Collins based pharma-biologics company, has used mass spectrometry services to detect oxidation in recombinant protein samples manufactures for human terapeutics. OPX Biotechnologies based in Boulder utilizes mass spectrometry to detect levels of intracellular metabolytes in biofuel molecule samples. Longmont-based Avery Brewing Co. has partnered with the Next-Generation DNA Sequencing Facility to develop an early-detection test for yeast cross-contamination to reduce waste and inefficiencies in their production process. Visit: http://biofrontiers.colorado.edu
Link to the PitchEngine social media news release
Thursday, November 14, 2013
"The Colorado Office of Economic Development and International Trade (OEDIT) today announced grantees for the Commercialization Infrastructure grants under the Bioscience Discovery Evaluation Grant Program (BDEGP). A total of $3,135,000 was awarded to support key industry infrastructure that facilitates drug discovery and lifts new bio-tech, life-science businesses off the ground.
'Congratulations to our deserving grantees who provide critical services to the bioscience industry and the state,' said Sonya Guram, program manager at OEDIT. 'The organizations provide key assets that we want to make solid for the long-term.'
* The Colorado Institute for Drug, Device and Diagnostic Development: $1,350,000
* Colorado Center for Drug Discovery: $750,000
* The Skaggs School of Pharmacy and Pharmaceutical Sciences at the Univ of Colorado: $410,248
* The BioFrontiers Institute at the University of Colorado: $624,752"
Link to the OEDIT news release
Link to a recap by Greg Avery/Denver Business Journal
"The Boulder Valley has a reputation as a hub for cancer-treatment drug research — especially targeting lung cancer — according to company representatives and an industry trade group.
Seven companies based in Boulder, Longmont and Louisville focus on cancer-related research, according to a Colorado BioScience Association database. The Denver-based industry trade group identified Boulder BioTechnology Inc., Clovis Oncology Inc., Siva Therapeutics Inc., SuviCa Inc. and Array BioPharma Inc., all in Boulder, as cancer research companies. GlobeImmune Inc. in Louisville and OnKure Inc. in Longmont also made the list...
...Laboratories related to the University of Colorado’s four campuses and veterinary studies at Colorado State University have led to a broad culture of innovation in cancer research, said April Giles, executive director of the Colorado BioScience Association. Several companies in Boulder and Broomfield counties are members of the group."
Link to the full article
Monday, November 11, 2013
Tim Schultz, President and Executive Director of Boettcher Foundation, introduced the 2013 Class of Boettcher Investigators to the Colorado bioscience community at the Colorado BioScience Association (CBSA)Tenth Annual Awards Dinner on November 7 at the Marriott City Center in Denver. Video:
The 2013 (fourth) Class of Boettcher Investigators in the Webb-Waring Biomedical Research Program includes:
* Dr. Amrut V. Ambardekar, M.D., University of Colorado Anschutz Medical Campus, Assistant Professor of Medicine — Cardiology, Myocardial Recovery After Ventricular Assist Device Implantation
* Dr. Joseph A. Brzezinski, Ph.D., University of Colorado Anschutz Medical Campus, Assistant Professor of Ophthalmology, Mechanisms of Retinal Development and Disease
* Dr. Soyeon Park, Ph.D., University of Colorado Boulder, Assistant Professor of Molecular, Cellular and Developmental Biology, Molecular Mechanisms of Proteasome Biogenesis
* Dr. Abigail L. Person, Ph.D., University of Colorado Anschutz Medical Campus, Assistant Professor of Physiology and Biophysics, Corollary Discharge Pathways Underlying Schizophrenia Symptoms
* Dr. Michael Strong, Ph.D., National Jewish Health, Assistant Professor of Genes, Environment, and Health, Genomics of Respiratory Disease Associated Pathogens
* Dr. Lucas Argueso, Ph.D., Colorado State University, Assistant Professor of Radiation and Cancer Biology, Gene Copy Number Variation
* Dr. Brad Borlee, Ph.D., Colorado State University, Assistant Professor of Bacteriology, Molecular Regulation of Bacterial Pathogenesis
* Dr. Melissa Krebs, Ph.D., Colorado School of Mines, Assistant Professor of Chemical and Biological Engineering, Controlled Delivery of Therapeutics from Biopolymer Systems
With the addition of the 2013 Class, there are now 22 Boettcher Investigators conducting research in the following Colorado institutions: University of Colorado Anschutz Medical Campus, University of Colorado Boulder, Colorado State University, National Jewish Health and Colorado School of Mines. All grant awards are $225,000.
Link to the related May 30th Business Wire
Sunday, November 10, 2013
"The Colorado BioScience Association has given special awards to industry players who made the most notable acheivements and contributions during the group’s 10-year history."
Link to the Denver Business Journal